Maxigen Biotech (TPE:1783) Cyclically Adjusted FCF per Share: NT$1.59 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$40.15
GF Value NT$61.40
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Cyclically Adjusted FCF per Share?

Maxigen Biotech TPE:1783 87 Cyclically Adjusted FCF per Share is NT$1.59 as of Dec. 2025. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.40 (Significantly Undervalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Maxigen Biotech's adjusted free cash flow per share for the three months ended in Dec. 2025 was NT$0.594. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$1.59 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Maxigen Biotech's average Cyclically Adjusted FCF Growth Rate was 69.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 216.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Maxigen Biotech was 216.80% per year. The lowest was 216.80% per year. And the median was 216.80% per year.

As of today (2026-07-22), Maxigen Biotech's current stock price is NT$40.15. Maxigen Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2025 was NT$1.59. Maxigen Biotech's Cyclically Adjusted Price-to-FCF of today is 25.25.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Maxigen Biotech was 1255.24. The lowest was 23.96. And the median was 58.41.


Maxigen Biotech  (TPE:1783) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Maxigen Biotech's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=40.15/1.59
=25.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Maxigen Biotech was 1255.24. The lowest was 23.96. And the median was 58.41.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Maxigen Biotech Cyclically Adjusted FCF per Share Related Terms


Maxigen Biotech Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech Cyclically Adjusted FCF per Share Chart

Maxigen Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.24 0.05 0.37 0.94 1.59

Maxigen Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 1.16 1.26 1.48 1.59

TPE:1783 vs ISRG, BDX, MDLN: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Cyclically Adjusted Price-to-FCF falls into.


TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Maxigen Biotech's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.594/324.0540*324.0540
=0.594

Current CPI (Dec. 2025) = 324.0540.

Maxigen Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 -0.456 238.132 -0.621
201606 -0.220 241.018 -0.296
201609 0.259 241.428 0.348
201612 -0.055 241.432 -0.074
201703 -0.335 243.801 -0.445
201706 -0.039 244.955 -0.052
201709 0.172 246.819 0.226
201712 0.480 246.524 0.631
201803 0.488 249.554 0.634
201806 0.622 251.989 0.800
201809 0.270 252.439 0.347
201812 0.324 251.233 0.418
201903 0.114 254.202 0.145
201906 -0.137 256.143 -0.173
201909 0.315 256.759 0.398
201912 0.546 256.974 0.689
202003 -0.114 258.115 -0.143
202006 -0.209 257.797 -0.263
202009 0.326 260.280 0.406
202012 0.783 260.474 0.974
202103 0.260 264.877 0.318
202106 0.087 271.696 0.104
202109 0.388 274.310 0.458
202112 0.639 278.802 0.743
202203 0.565 287.504 0.637
202206 0.641 296.311 0.701
202209 0.805 296.808 0.879
202212 0.822 296.797 0.897
202303 0.185 301.836 0.199
202306 0.793 305.109 0.842
202309 0.155 307.789 0.163
202312 0.540 306.746 0.570
202403 0.508 312.332 0.527
202406 0.458 314.175 0.472
202409 1.254 315.301 1.289
202412 0.769 315.605 0.790
202503 0.732 319.799 0.742
202506 0.299 322.561 0.300
202509 0.679 324.800 0.677
202512 0.594 324.054 0.594

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$1.59 mean?
Maxigen Biotech (TPE:1783) has a Cyclically Adjusted FCF per Share of NT$1.59 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Maxigen Biotech and its competitors.
Is Maxigen Biotech's Cyclically Adjusted FCF per Share too high?
Maxigen Biotech's current Cyclically Adjusted FCF per Share is NT$1.59. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Cyclically Adjusted FCF per Share compare to ISRG and BDX?
Maxigen Biotech's Cyclically Adjusted FCF per Share of NT$1.59 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current Cyclically Adjusted FCF per Share is NT$1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.40, compared to a current price of NT$40.15 — trading 34.6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$1.59. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Cyclically Adjusted FCF per Share is NT$1.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$40.15 is trading 34.6% below its estimated GF Value™ of NT$61.40. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Cyclically Adjusted FCF per Share: NT$1.59
  • GF Value™: NT$61.40 vs. price of NT$40.15 (34.6% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.15
Price
NT$61.40
GF Value